Report: Sequencing-Based Test Market Already Highly Competitive
NEW YORK, Feb. 24, 2015 /PRNewswire/ -- In a sign that next-generation sequencing has reached the clinical laboratory, Kalorama Information says there are over 50 companies that offering sequencing-based tests through their own CLIA-certified laboratories. The market research firm said companies like Quest and bioMeriuex, Sequenom and Novartis offer a wide range of tests where sequencing can be used to detect disease susceptibility or presence, and that smaller reference laboratories are also competing in the field.
The finding was made in Kalorama Information's Next Generation Sequencing Markets 2015.
"These firms and reference laboratories offer next-gen sequencing that they perform and charge for as a service," said Bruce Carlson, publisher of Kalorama. "Increased risk for breast and colon cancers, childhood epilepsy, renal disorders, prenatal tests and many others are available now."
The report, featuring detailed information on top market competitors, can be obtained at: http://www.kaloramainformation.com/Generation-Sequencing-Systems-8743599/.
Next generation sequencing experiments can rapidly generate large amounts of data that can be challenging to evaluate and understand. In research applications, much of this data is often generated on regions of the genome where it is not yet known what the significance of genetic changes may be. This data can be valuable for researchers trying to answer some of the many questions regarding the genome and disease. However, results from these experiments do not generate results that a clinician can use when making treatment decisions.
Kalorama notes that it is the diagnostic companies who have realized the importance of more targeted sequencing approaches that focus on genes for which the clinical utility of genetic changes is known. In addition, DNA sequencing platforms have traditionally been expensive, and using these instruments to test samples has been complex – with the requirements for sample preparation, sequencing, and then analysis and interpretation of the results. This has made it difficult to follow the traditional in vitro diagnostic (IVD) approach of developing kits that can be sold to clinical laboratories that perform the tests on instruments in their laboratory. As a result, many of the diagnostic applications of sequencing have traditionally been performed by clinical laboratories, or by diagnostic companies that establish their own CLIA-certified laboratory.
The following are among the companies with testing services that Kalorama details in the report:
- Adaptive Biotechnologies Corporation
- Admera Health
- Ambry Genetics Corp.
- ARUP Laboratories
- Athena Diagnostics, Inc.
- bioTheranostics
- Blueprint Genetics
- CareDx, Inc.
- Cleveland Clinic Laboratories
- Counsel, Inc.
- Courtagen Life Sciences, Inc.
- DioGenix, Inc.
- GeneDx
- Genomic Health, Inc.
- Genoptix (A Novartis Company)
- Intellimedix
- InVitae Corporation
- Laboratory Corporation of America (LabCorp)
- LifeCodexx AG
- Mayo Medical Laboratories
- MedGenome Labs Pvt. Ltd.
- Medical Diagnostic Laboratories, L.L.C.
- MEDomics, LLC
- MOgene Clinical Diagnostics (MOgeneDx), LC
- MolecularMD Corporation
- NeoGenomics Laboratories
- NewGene Ltd.
- Parabase Genomics
- Pathway Genomics Corporation
- Personalis, Inc.
- PreventionGenetics
- Quest Diagnostics
- Reprogenetics, LLC
- Roswell Park Cancer Institute
- Sequenom Inc.
- Sequenta, Inc.
- Sundance Diagnostics, Inc.
- Symbiodx
- Transgenomic, Inc.
Kalorama's report provides more detail on the test offerings of each company. Next Generation Sequencing Markets 2015 also includes detailed tables indicating the activities of competitors in the market. The report breaks out system, consumable and service segments and provides information on brand ownership and regional installed base of sequencers. The report can be purchased at: http://www.kaloramainformation.com/Generation-Sequencing-Systems-8743599/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Related Links
http://www.kaloramainformation.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article